Clinical and biochemical effects of a 3-week program of diet combined with spa therapy in obese and diabetic patients: a pilot open study.

Obesity is a major risk factor for arterial hypertension, coronary artery disease, dyslipidemias, and type 2 diabetes. Spa therapy has long been used for treating obesity and its comorbidities. Enlargement of adipose tissue has been linked to a dysregulation of adipokine secretion and adipose tissue inflammation. Adipokines are currently investigated as potential drug targets in these conditions. Our primary aim was to assess the clinical efficacy of a 3-week program of diet combined with spa therapy in obese patients with and without type 2 diabetes. The secondary aim was to examine whether this combined program influences the response of serum levels of leptin, adiponectin, visfatin, and high-sensitivity C-reactive protein. Fifty obese males were enrolled and 21 of these featured a type 2 diabetes. During the 3-week period of the study, the patients were on a 1,000-kcal diet and were involved in mineral bath and total body's mud-pack applications (15 procedures). Patients were assessed at baseline and at the end of the therapy for clinical and biochemical parameters (total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glycemia, and adipokines). We showed that a 3-week program of spa therapy in obese patients induced significant decrease of body weight, body mass index, triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, glycemia, and serum levels of leptin and high-sensitivity C-reactive protein. So, a cycle of mud-bath therapy associated with a controlled diet may be a promising treatment for obesity and type 2 diabetes decreasing body weight and many risk factors for atherosclerosis and metabolic syndrome.

[Nonalcoholic fatty liver disease in obese patients]. / Niealkoholowe stluszczenie watroby u osób otylych.

INTRODUCTION: Nonalcoholic fatty liver disease (NFLD) is a heavy healthy problem in well civilized Countries, where obese appear more frequently. Mostly disease has a benign process, but in some radical case might lead to cirrhosis or even to cancer. There is a demand on specific researches about NFLD, cause knowledge about pathogenesis and epidemiology is not clear. The aim of this researches is to rate frequency of occurring nonalcoholic fatty liver disease in obese type II and III patients with reference to patients with correct body weight. MATERIAL AND METHODS: Research group comprise 70 patients of Clinical Health Resort Hospital in Ciechocinek with BMI higher than 35. Control group comprise 20 patients with BMI lower than 30. In case of all patients fatty liver qualities were rate by ultrasounds scaning examination. For additional diagnostic following parameters were rated: liver enzyme ASPAT/ALAT levels, lipids level, glycemic level before and after meal. RESULTS: In case of 52 patients from research group fatty liver qualities were noticed, it is about 65% of whole group. Much more often fatty liver qualities had been noticed about patients witch III degree of obese (94%). In control group we didn't notice fatty liver qualities in any patients. ALAT level was statistical relevant (p = 0.0006) higher in research group (32 U/l) then level in control group (20,3 U/I). ASPAT level in research group amounted to 28.7 U/l and in control group only 19.8 U/l. Difference between those two group was statistical relevant (p = 0.0005). CONCLUSION: Nonalcoholic fatty liver disease occur average in case of 65% obese patients but in cease of patients with III degree obese is about 94%. That disease ought to be treated like a complication of obese.